Document is current
Any future updates will be listed below
-
Authors
Sacco, Simona https://orcid.org/0000-0003-0651-1939
Benemei, Silvia
Cevoli, Sabina
Coppola, Gianluca
Cortelli, Pietro
De Cesaris, Francesco
De Icco, Roberto
De Marco, Cristiano Maria
Di Lorenzo, Cherubino
Geppetti, Pierangelo
Manni, Alessia
Negro, Andrea
Ornello, Raffaele
Pierangeli, Giulia
Pierelli, Francesco
Pellesi, Lanfranco
Pini, Luigi Alberto
Pistoia, Francesca
Prudenzano, Maria Pia
Russo, Antonio
Sances, Grazia
Taranta, Valentina
Tassorelli, Cristina
Tedeschi, Gioacchino
Trojano, Maria
Martelletti, Paolo
-
Funding
Funding for this research was provided by:
Fondazione Italiana per lo Studio delle Cefalee (NA)
- License Information
-
More Information
Article History
Received: 30 October 2018
Accepted: 24 January 2019
First Online: 13 February 2019
Ethics approval and consent to participate
: The study was approved by the local Ethics Committee of each of the 9 participating tertiary Headache Centers. Each participant in the study signed an informed written consent.
: Not applicable.
: SS: Allergan, Novartis, TEVA, Eli Lilly; SB: IBSA; SC: none; GC: none; PC: none; FDC: Allergan, Angelini, Lusofarmaco; RDI: none; CDM: none; CDL: none; PG: Allergan, Eli Lilly, IBSA, Chiesi, Novartis, TEVA; AM: none; AN: Allergan, Novartis; RO: none; GP: none; FP: Novartis, Teva; LP: none; LAP: none; FP: none; MPP: Novartis, Teva, Almirall; AR: Allergan, Novartis, Teva; GS: Allergan, Novartis, Teva, Eli Lilly, Alder, IBSA; VT: none; CT: Allergan, Electrcocore, Eli Lilly, Novartis, Teva; GT: Allergan, Novartis, Teva, Sanofi, Biogen; MT: none; PM: Allergan, Amgen, Novartis, Teva.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
